The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...
Tyrosine kinase inhibitors with and without upfront CNS radiation for brain metastases in oncogene-driven non-small cell lung cancer (TURBO-NSCLC). This is an ASCO Meeting Abstract from the 2024 ASCO ...
The theme for the 2025 American Society for Radiation Oncology (ASTRO) annual meeting was "Rediscovering Radiation Medicine and Exploring New Indications." In both small-cell lung cancer (SCLC) and ...
Hosted on MSN
At 10 years, stereotactic body radiation therapy comparable to surgery for early-stage lung cancer
Researchers from The University of Texas MD Anderson Cancer Center will present new data at the American Society for Radiation Oncology (ASTRO) 2025 Annual Meeting demonstrating that stereotactic body ...
Long-term experience using high-dose stereotactic body radiotherapy (SBRT) confirms that this highly focused, rigidly delivered, and tightly controlled radiation approach results in excellent local ...
Researchers from The University of Texas MD Anderson Cancer Center will present new data at the American Society for Radiation Oncology (ASTRO) 2025 Annual Meeting demonstrating that stereotactic body ...
Study is the first to compare 10-year outcomes from surgery and a specific kind of radiation therapy known as SBRT (also called SABR) in non-small cell lung cancer Survival outcomes were similar, but ...
Stereotactic radiosurgery (SRS) and stereotactic ablative body radiotherapy (SABR) have revolutionized precision oncology by delivering high‐dose, conformal radiation with submillimeter accuracy.
Ayal Aizer, MD, MHS, explains how expanded trial data have broadened eligibility for stereotactic radiosurgery in patients with brain metastases, including higher tumor counts. For years, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results